Dr. Milind Deshpande advises Peptone on drug discovery and development. He brings more than 25 years of leadership across the drug development lifecycle and led early discovery programs in infectious diseases and neuroscience at Bristol Myers Squibb. He co-invented the HCV NS5A inhibitors that led to Daklinza, later led Achillion Pharmaceuticals, and now serves as a Venture Partner at RA Capital and President and CEO of Nayan Therapeutics.
Scientific Advisor for Drug Discovery and Development